632 related articles for article (PubMed ID: 25637496)
21. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
[TBL] [Abstract][Full Text] [Related]
22. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
[TBL] [Abstract][Full Text] [Related]
24. [Detection and Analysis of EGFR and KRAS Mutations
in the Patients with Lung Squamous Cell Carcinomas].
Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Su D; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):621-5. PubMed ID: 26483334
[TBL] [Abstract][Full Text] [Related]
25. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.
Conde E; Angulo B; Izquierdo E; Muñoz L; Suárez-Gauthier A; Plaza C; Dominguez N; Torres M; Madrigal L; Rubio-Viqueira B; Belda-Iniesta C; Hidalgo M; López-Ríos F
Histopathology; 2013 Mar; 62(4):609-16. PubMed ID: 23379755
[TBL] [Abstract][Full Text] [Related]
26. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
27. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
[TBL] [Abstract][Full Text] [Related]
29. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.
Horiike A; Kimura H; Nishio K; Ohyanagi F; Satoh Y; Okumura S; Ishikawa Y; Nakagawa K; Horai T; Nishio M
Chest; 2007 Jun; 131(6):1628-34. PubMed ID: 17565015
[TBL] [Abstract][Full Text] [Related]
30. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
31. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
[TBL] [Abstract][Full Text] [Related]
32. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
[TBL] [Abstract][Full Text] [Related]
33. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".
Arrieta O; Ramírez-Tirado LA; Báez-Saldaña R; Peña-Curiel O; Soca-Chafre G; Macedo-Perez EO
Lung Cancer; 2015 Nov; 90(2):161-6. PubMed ID: 26358312
[TBL] [Abstract][Full Text] [Related]
34. EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.
Bircan S; Baloglu H; Kucukodaci Z; Bircan A
Med Oncol; 2014 Aug; 31(8):87. PubMed ID: 24973952
[TBL] [Abstract][Full Text] [Related]
35. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
37. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
[TBL] [Abstract][Full Text] [Related]
39. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
[TBL] [Abstract][Full Text] [Related]
40. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
